PPARGC1A and melanoma: As the activation of the Wnt/β-Catenin pathway in melanoma guides resistance to anti-PD-L1/anti-CTLA-4 treatment (128, 129), targeting the Wnt/β-Catenin signaling pathway or PGC1α may improve the effectiveness of immunotherapy by inducing ferroptosis (129).